Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopath...
Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK
About this item
Full title
Author / Creator
Publisher
BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
PurposeTo compare the efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy (PCV) over 96 weeks in the HAWK study.DesignHAWK was a global, 2-year, randomised, double-masked, multicentre phase III trial in participants with neovascular age-related macular degeneration.MethodsOf the Japanese participant...
Alternative Titles
Full title
Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9234403
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9234403
Other Identifiers
ISSN
0007-1161
E-ISSN
1468-2079
DOI
10.1136/bjophthalmol-2021-319090
